FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065434413> ?p ?o ?g. }

• W2065434413 endingPage "521" @default.
• W2065434413 startingPage "512" @default.
• W2065434413 abstract "OBJECTIVE To assess maintenance of efficacy and tolerability of gabapentin enacarbil in patients with moderate to severe primary restless legs syndrome (RLS). PATIENTS AND METHODS This study (conducted April 18, 2006, to November 14, 2007) comprised a 24-week, single-blind (SB) treatment phase (gabapentin enacarbil, 1200 mg) followed by a 12-week randomized, double-blind (DB) phase. Responders from the SB phase (patients with improvements on the International Restless Legs Scale [IRLS] and investigator-rated Clinical Global Impression–Improvement scale at week 24 and stable while taking a gabapentin enacarbil dose of 1200 mg for at least 1 month before randomization) were randomized to gabapentin enacarbil, 1200 mg, or placebo once daily at 5 pm with food. The primary end point was the proportion of patients experiencing relapse (worse scores on the IRLS and investigator-rated Clinical Global Impression of Change scale on 2 consecutive visits at least 1 week apart or withdrawal because of lack of efficacy) during the DB phase. RESULTS A total of 221 of 327 patients completed the SB phase, 194 (96 in the gabapentin enacarbil group and 98 in the placebo group) were randomized to DB treatment, and 168 (84 in the gabapentin enacarbil group and 84 in the placebo group) completed the DB phase. A significantly smaller proportion of patients treated with gabapentin enacarbil (9/96 [9%]) experienced relapse compared with the placebo-treated patients (22/97 [23%]) (odds ratio, 0.353; 95% confidence interval, 0.2-0.8; P=.02). Somnolence and dizziness were the most common adverse events. One death occurred (unintentional choking during the SB phase) and was judged as being unrelated to the study drug. No clinically relevant changes were observed in laboratory values, in vital signs, or on electrocardiograms. CONCLUSION Gabapentin enacarbil, 1200 mg, maintained improvements in RLS symptoms compared with placebo and showed long-term tolerability in adults with moderate to severe primary RLS for up to 9 months of treatment. To assess maintenance of efficacy and tolerability of gabapentin enacarbil in patients with moderate to severe primary restless legs syndrome (RLS). This study (conducted April 18, 2006, to November 14, 2007) comprised a 24-week, single-blind (SB) treatment phase (gabapentin enacarbil, 1200 mg) followed by a 12-week randomized, double-blind (DB) phase. Responders from the SB phase (patients with improvements on the International Restless Legs Scale [IRLS] and investigator-rated Clinical Global Impression–Improvement scale at week 24 and stable while taking a gabapentin enacarbil dose of 1200 mg for at least 1 month before randomization) were randomized to gabapentin enacarbil, 1200 mg, or placebo once daily at 5 pm with food. The primary end point was the proportion of patients experiencing relapse (worse scores on the IRLS and investigator-rated Clinical Global Impression of Change scale on 2 consecutive visits at least 1 week apart or withdrawal because of lack of efficacy) during the DB phase. A total of 221 of 327 patients completed the SB phase, 194 (96 in the gabapentin enacarbil group and 98 in the placebo group) were randomized to DB treatment, and 168 (84 in the gabapentin enacarbil group and 84 in the placebo group) completed the DB phase. A significantly smaller proportion of patients treated with gabapentin enacarbil (9/96 [9%]) experienced relapse compared with the placebo-treated patients (22/97 [23%]) (odds ratio, 0.353; 95% confidence interval, 0.2-0.8; P=.02). Somnolence and dizziness were the most common adverse events. One death occurred (unintentional choking during the SB phase) and was judged as being unrelated to the study drug. No clinically relevant changes were observed in laboratory values, in vital signs, or on electrocardiograms. Gabapentin enacarbil, 1200 mg, maintained improvements in RLS symptoms compared with placebo and showed long-term tolerability in adults with moderate to severe primary RLS for up to 9 months of treatment." @default.
• W2065434413 created "2016-06-24" @default.
• W2065434413 creator A5022673217 @default.
• W2065434413 creator A5025014357 @default.
• W2065434413 creator A5038882344 @default.
• W2065434413 creator A5056529315 @default.
• W2065434413 creator A5084367532 @default.
• W2065434413 date "2010-06-01" @default.
• W2065434413 modified "2023-10-16" @default.
• W2065434413 title "Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study" @default.
• W2065434413 cites W1535948728 @default.
• W2065434413 cites W1547646341 @default.
• W2065434413 cites W1969281286 @default.
• W2065434413 cites W1976248829 @default.
• W2065434413 cites W1976600878 @default.
• W2065434413 cites W1980626997 @default.
• W2065434413 cites W1984954458 @default.
• W2065434413 cites W1985008430 @default.
• W2065434413 cites W1991024180 @default.
• W2065434413 cites W2011861063 @default.
• W2065434413 cites W2012714739 @default.
• W2065434413 cites W2024039333 @default.
• W2065434413 cites W2030663930 @default.
• W2065434413 cites W2034430472 @default.
• W2065434413 cites W2038810061 @default.
• W2065434413 cites W2041988152 @default.
• W2065434413 cites W2043201355 @default.
• W2065434413 cites W2050735454 @default.
• W2065434413 cites W2051303382 @default.
• W2065434413 cites W2058182118 @default.
• W2065434413 cites W2072667894 @default.
• W2065434413 cites W2075712240 @default.
• W2065434413 cites W2084813391 @default.
• W2065434413 cites W2085156752 @default.
• W2065434413 cites W2088888105 @default.
• W2065434413 cites W2091605545 @default.
• W2065434413 cites W2103475556 @default.
• W2065434413 cites W2137606403 @default.
• W2065434413 cites W2156260991 @default.
• W2065434413 cites W2163740408 @default.
• W2065434413 cites W2169879202 @default.
• W2065434413 doi "https://doi.org/10.4065/mcp.2009.0700" @default.
• W2065434413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2878254" @default.
• W2065434413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20511481" @default.
• W2065434413 hasPublicationYear "2010" @default.
• W2065434413 type Work @default.
• W2065434413 sameAs 2065434413 @default.
• W2065434413 citedByCount "62" @default.
• W2065434413 countsByYear W20654344132012 @default.
• W2065434413 countsByYear W20654344132013 @default.
• W2065434413 countsByYear W20654344132014 @default.
• W2065434413 countsByYear W20654344132015 @default.
• W2065434413 countsByYear W20654344132016 @default.
• W2065434413 countsByYear W20654344132017 @default.
• W2065434413 countsByYear W20654344132018 @default.
• W2065434413 countsByYear W20654344132019 @default.
• W2065434413 countsByYear W20654344132020 @default.
• W2065434413 countsByYear W20654344132021 @default.
• W2065434413 countsByYear W20654344132022 @default.
• W2065434413 countsByYear W20654344132023 @default.
• W2065434413 crossrefType "journal-article" @default.
• W2065434413 hasAuthorship W2065434413A5022673217 @default.
• W2065434413 hasAuthorship W2065434413A5025014357 @default.
• W2065434413 hasAuthorship W2065434413A5038882344 @default.
• W2065434413 hasAuthorship W2065434413A5056529315 @default.
• W2065434413 hasAuthorship W2065434413A5084367532 @default.
• W2065434413 hasBestOaLocation W20654344132 @default.
• W2065434413 hasConcept C126322002 @default.
• W2065434413 hasConcept C142724271 @default.
• W2065434413 hasConcept C168563851 @default.
• W2065434413 hasConcept C197934379 @default.
• W2065434413 hasConcept C204243189 @default.
• W2065434413 hasConcept C204787440 @default.
• W2065434413 hasConcept C27081682 @default.
• W2065434413 hasConcept C2776000289 @default.
• W2065434413 hasConcept C2776608144 @default.
• W2065434413 hasConcept C2776750294 @default.
• W2065434413 hasConcept C2778375690 @default.
• W2065434413 hasConcept C2779034229 @default.
• W2065434413 hasConcept C2781210498 @default.
• W2065434413 hasConcept C42219234 @default.
• W2065434413 hasConcept C44249647 @default.
• W2065434413 hasConcept C71924100 @default.
• W2065434413 hasConcept C98274493 @default.
• W2065434413 hasConceptScore W2065434413C126322002 @default.
• W2065434413 hasConceptScore W2065434413C142724271 @default.
• W2065434413 hasConceptScore W2065434413C168563851 @default.
• W2065434413 hasConceptScore W2065434413C197934379 @default.
• W2065434413 hasConceptScore W2065434413C204243189 @default.
• W2065434413 hasConceptScore W2065434413C204787440 @default.
• W2065434413 hasConceptScore W2065434413C27081682 @default.
• W2065434413 hasConceptScore W2065434413C2776000289 @default.
• W2065434413 hasConceptScore W2065434413C2776608144 @default.
• W2065434413 hasConceptScore W2065434413C2776750294 @default.
• W2065434413 hasConceptScore W2065434413C2778375690 @default.
• W2065434413 hasConceptScore W2065434413C2779034229 @default.
• W2065434413 hasConceptScore W2065434413C2781210498 @default.
• W2065434413 hasConceptScore W2065434413C42219234 @default.

• next